



# Anti-Inflammatory and Antinociceptive Activities of the Ethanolic Extract of Propolis in Male Mice and Rats

Rahmatollah Parandin <sup>1,\*</sup> and Shahzad Daroogari <sup>1</sup>

<sup>1</sup>Department of Biology, Payame Noor University, Tehran, Iran

\*Corresponding author: Department of Biology, Payame Noor University, Artesh Highway, Nakhil St., Tehran, Iran. Email: rahmatparandin@pnu.ac.ir

Received 2018 September 10; Revised 2019 February 05; Accepted 2019 February 26.

## Abstract

**Background:** Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually used to alleviate pain and inflammation. The widespread use of NSAIDs has caused the risk and side effects of these drugs commonly increase.

**Objectives:** This study aimed to examine the anti-inflammatory and antinociceptive activities of ethanolic extract of propolis (EEP) in male mice and rats.

**Methods:** In this experimental study, EEP was prepared and administered in doses of 100, 200, and 400 mg/kg of body weight. The anti-inflammatory potential was assessed by inflammatory models of xylene-induced ear edema and cotton pellet granuloma tests, whereas the antinociceptive potential was assessed by formalin and acetic acid-induced writhing methods.

**Results:** The EEP at doses of 100 ( $P < 0.05$ ), 200 ( $P < 0.001$ ) and 400 mg/kg ( $P < 0.001$ ) significantly diminished the foundation of edema caused by xylene. A significant decrease was seen in granuloma weight in EEP at doses of 200 ( $P < 0.001$ ) and 400 mg/kg ( $P < 0.001$ ). The extract caused a significant decrease in licking time at first phase in EEP at 100 ( $P < 0.01$ ), 200 ( $P < 0.001$ ), and 400 mg/kg ( $P < 0.001$ ). A significant decrease was observed ( $P < 0.001$ ) in licking time at the second phase in EEP at doses of 100, 200, and 400 mg/kg. In the writhing model, a significant decrease was observed in the number of writhes in EEP at doses of 100 ( $P < 0.05$ ), 200 ( $P < 0.001$ ), and 400 mg/kg ( $P < 0.001$ ).

**Conclusions:** The findings of this research showed that the ethanolic extract of propolis has considerable anti-inflammatory and antinociceptive activities.

**Keywords:** Propolis, Anti-Inflammatory, Antinociceptive, Mice, Rat

## 1. Background

The inflammation usually occurs in response to injurious stimuli, including physical injury, trauma, infectious microorganisms, toxic chemical substances, ischemia, or tumor growth (1, 2). Some characteristics of inflammatory responses are comprised of pain, swelling, heat, redness, edema, and loss of function (3). The inflammation consists of different phases, including the release of chemotactic factors, increased blood circulation, and increased capillary permeability, allowing for cellular infiltration, followed by either an acute resolution of tissue damage or persistence of the response that might contribute to fibrosis or dysfunction of the tissues and organs (4). Although inflammation is a defense mechanism, it could be disadvantageous if the stimulus insists for long-term courses as it may cause painful inflammatory problems, including gastritis, arthritis, etc. (5). The inflammation is generally related to pain as a secondary mechanism, caused by secretion of analgesic mediators (6). Pain as an unsightly feel-

ing can be either acute or chronic and it is an outcome of involved neurochemical mechanisms in the nervous system (7). In addition, pain is the most common reason for seeking medical and pharmaceutical care and it is the most prevalent sign of various pathologies and imposes a high expenditure of pharmaceutical and health burden on the society (8).

Although the inflammation and pain are commonly remedied by nonsteroidal anti-inflammatory drugs (NSAIDs), their long-term use is closely associated with serious toxic effects, including gastrointestinal ulcers, renal disorders, hepatic abnormalities, and metabolic disturbances (9-11). In addition, opioids (narcotics), including natural (derived from the opium poppy plant) and synthetic narcotics are potent drugs in reducing the swelling and pain. Opioid drugs have diverse psychological and physical side effects such as gastrointestinal bleeding, nausea and vomiting, cognitive impairment, respiratory depression, hyperalgesia, endocrine-hypogonadism, tol-

erance, withdrawal, and addiction (12-17). Therefore, there are efforts to find safe and new anti-inflammatory and analgesic medications with the least side effects. Traditional medicine and medicinal plants are extensively used in reducing the swelling and pain symptoms (18, 19).

Propolis or bee glue is a gummy resinous material that honey bees amass it from plant exudates to make seal holes in the beehive (20, 21). Because of waxy and supple quiddity of propolis, honey bees exploit it in the making and renovation of their beehive (22, 23). In addition, many studies have shown that there are about 300 compounds in propolis, including resin (50%), wax (30%), essential oils (10%), pollen (5%), and other organic compounds (5%) (24, 25). Propolis has useful effects on body health and it has been extensively used in folk medicine to treat many illnesses for many years. The Greek and the Roman physicians also acknowledged the potential of propolis by employing it in wound treatment, as an antiseptic and cicatrizing agent, and as mouth disinfectant. The Persians used propolis in eczemas, myalgia, and rheumatism remedy. The Incas also described propolis as an antipyretic drug (26, 27). In the past few years, numerous literatures have been attributed to propolis activities such as anti-inflammatory, anti-tumoral, antiviral, antibacterial, anti-fungal, and antinociceptive (24-28). Propolis activates immune cells that produce cytokines (28). It is also used to treat muscle and articulation inflammations, infections, rheumatisms, and torsions (29).

## 2. Objectives

This research aimed to test the effects of propolis on inflammatory and nociceptive models in male mice and rats.

## 3. Methods

This experimental study was performed in 2018 at Payame Noor University, Kermanshah, Iran. This study was approved by the Research Ethics Committee of Payame Noor University (code: IR.PNU.REC.1397.080) and carried out according to the ethical guidelines for experimental investigation in animals.

Preparation of ethanolic extract of propolis: Approximately 100 g propolis was obtained from bees' hives in Ardebil province, Iran and stored at 4°C. After dehydration, the dried samples were ground to make a fine powder. Ethanolic extract of propolis (EEP) was prepared by adding 2 g of powder to 25 mL of 10% - 95% ethanol in tubes and shaking at 70°C for 30 minutes. In the next step, the extract was centrifuged to acquire the supernatant (30).

### 3.1. Animals

Animals used in this study were comprised of 90 male BALB/c mice (25 - 30 g) and 30 male Wister rats (250 - 300 g). They were maintained at a humidity of  $50 \pm 5\%$ , a temperature of  $22 \pm 1^\circ\text{C}$ , with a 12 hours light/dark cycle, and given ad libitum access to food and water.

### 3.2. Anti-Inflammatory Study

#### 3.2.1. Xylene-Induced Ear Edema

For acute inflammation assessment, 30 mice were randomly assigned to five groups of 6 animals, including EEP (100, 200, and 400 mg/kg), positive control (dexamethasone, 15 mg/kg) or normal saline (the control group). Dexamethasone, commonly used as positive control anti-inflammatory agent, showed potent anti-inflammatory effects on xylene-induced ear edema. Sixty minutes after the intraperitoneal injections, 0.03 mL xylene was injected into the anterior surface of the right ear, while the left ear defined as the control. Two hours after the xylene injection, mice were deeply anesthetized and ears were removed. Circular sections were taken with a diameter of 7 mm and carefully weighed. An increase in the weight of the right ear punch compared with the left ear punch was indicated the edema (31).

#### 3.2.2. Cotton Pellet Granuloma

The chronic anti-inflammatory test carried out using cotton pellet granuloma model. Rats were randomly assigned to five groups ( $n=6$ ), including distilled water (control), indomethacin (10 mg/kg, the positive control), and 100, 200, and 400 mg/kg of EEP. Indomethacin, the positive control used in the study, which is known as an anti-inflammatory agent in cotton pellet granuloma model (32, 33). The animals were anesthetized with ketamine (100 mg/kg). In brief, after back skin disinfection with 70% ethanol and shave, a longitudinal incision of the skin was made in the lumbar region. Subcutaneous tunnels were created by blunted forceps and a sterilized, pre-weighed cotton pellet ( $15 \pm 1$  mg) was placed on both sides in the scapular region. Thirty minutes before the test, the animals were treated with distilled water, indomethacin, or extracts were orally-administered daily for 7 days. Then the animals were sacrificed in the 8th day, the pellets were dissected out, and dried in an oven at  $60^\circ\text{C}$  until the weight stabilized. Then the net dry weights and the percent inhibition increase in the weight of the cotton pellets were determined (32, 33).

### 3.3. Antinociception Study

#### 3.3.1. Formalin Test

Thirty mice were randomly assigned to five groups of 6 animals. In this test, 45 minutes prior to formalin test,

normal saline as the control, morphine (10 mg/kg) as the positive control or 100, 200 or 400 mg/kg of EEP were administered intraperitoneally. Morphine, commonly used as the positive control antinociceptive agent, showed potent analgesic effects on formalin test (34, 35). In this test, mice placed in a transparent enclosure, then 20  $\mu$ L of 2.5% formalin was injected into the right posterior paw. The formalin-induced paw licking response was designed as representative of the nociceptive behavior. After formalin injection, 0 - 5 and 20 - 30 minutes were recorded as the total time spent in licking and biting the injected paw (34, 35).

### 3.3.2. Acetic Acid-Induced Writhing

Thirty mice were randomly assigned to five groups of 6 animals. Forty-five minutes before the peritoneal irritation, mice were treated with EEP, 0.9% normal saline (control) and indomethacin (10 mg/kg) by oral administration. Then the animals were injected intraperitoneally with 1% acetic acid (0.1 mL/10g body weight). The writhing results were recorded after 10 minutes of acetic acid injection and counted for 10 minutes (34-37). Antinociceptive activity was distinguished by a decrease in the average of writhing numbers in the treatment groups compared with the control group, and it was calculated as %inhibition of abdominal constrictions using the following formula (37):  $[\text{mean of (control - test group)}/\text{control group} \times 100\%]$ .

### 3.4. Data Analysis

The results were described as mean  $\pm$  SEM and differences among groups were statistically excavated by one-way analysis of variance (ANOVA) followed by the Tukey method as a post hoc test. The significance level was set at  $P < 0.05$ .


## 4. Results

### 4.1. Xylene-Induced Ear Edema

The mean weight of ear edema in the control, dexamethasone, 100, 200 and 400 mg/kg of EEP groups was determined as  $18.5 \pm 0.92$ ,  $6.50 \pm 0.62$ ,  $14.17 \pm 0.75$ ,  $12.83 \pm 1.17$  and  $9.50 \pm 0.76$  mg, respectively. As shown in Figure 1, a significant decrease was observed in weight of ear edema in the dexamethasone ( $P < 0.001$ ), and EEP at 100 ( $P < 0.05$ ), 200 ( $P < 0.001$ ), and 400 mg/kg ( $P < 0.001$ ) in comparison to the control group.

### 4.2. Cotton Pellet Granuloma

As shown in Table 1, a significant decrease was observed in granuloma weight in the Indomethacin ( $P < 0.001$ ) and



**Figure 1.** Effects of EEP on xylene-induced ear edema in mice. N = 6, the values are shown as the mean  $\pm$  SEM, \* $P < 0.05$  and \*\*\* $P < 0.001$  vs. control.

**Table 1.** Effects of EEP on Cotton Pellet-Induced Granuloma in Rats<sup>a, b</sup>

Treatments	N	Granuloma wt., mg	Inhibition, %
Control	6	51.33 $\pm$ 1.74	-
Indomethacin	6	28.67 $\pm$ 1.78***	44.15
EEP100	6	46.17 $\pm$ 0.79	10.05
EEP200	6	41.50 $\pm$ 0.99***	19.15
EEP400	6	42.33 $\pm$ 0.80***	17.53

Abbreviation: EEP, ethanolic extract of propolis.

<sup>a</sup>The values are shown as the mean  $\pm$  SEM.

<sup>b</sup>\*\*\* $P < 0.001$  vs. control.

EEP (200 and 400 mg/kg,  $P < 0.001$ ), while EEP insignificantly decreased the granuloma weight at 100 mg/kg. At 100, 200, and 400 mg/kg of EEP, the percent reduction of granuloma weight was 10.05%, 19.15%, and 17.53%, respectively, as compared to the control group, whereas the standard drug indomethacin (10 mg/kg) showed a reduction of 44.15%.

### 4.3. Formalin Test

Results of the antinociceptive effects of EEP on pain induced by formalin in mice are shown in Table 2. Both phases of formalin-induced nociception were significantly inhibited in mice pretreated intraperitoneally with morphine and EEP. In the first phase (0 - 5 minutes), the inhibitions were 88.97% ( $P < 0.001$ ), 14.11% ( $P < 0.01$ ), 26.66% ( $P < 0.001$ ), and 62.31% ( $P < 0.001$ ) in morphine and EEP at 100, 200, and 400 mg/kg, respectively. In the second phase (20 - 30 minutes), the inhibitions were 89.85% ( $P < 0.001$ ), 25.73% ( $P < 0.001$ ), 46.40% ( $P < 0.001$ ), and 56.32% ( $P < 0.001$ ) in morphine and EEP at 100, 200, and 400 mg/kg, respectively.

**Table 2.** Effects of EEP on Formalin-Induced Paw Edema<sup>a,b</sup>

Treatments	N	First Phase (0 - 5 min)	Inhibition, %	Second Phase (20 - 30 min)	Inhibition, %
Control	6	65.00 ± 1.93	-	113.33 ± 2.32	-
Morphine	6	7.17 ± 0.31 <sup>***</sup>	88.97	11.50 ± 1.02 <sup>***</sup>	89.85
EEP100	6	55.83 ± 0.94 <sup>**</sup>	14.11	84.17 ± 2.34 <sup>***</sup>	25.73
EEP200	6	47.67 ± 1.47 <sup>***</sup>	26.66	59.67 ± 4.54 <sup>***</sup>	46.40
EEP400	6	24.50 ± 2.08 <sup>***</sup>	62.31	49.50 ± 5.91 <sup>***</sup>	56.32

Abbreviation: EEP, ethanolic extract of propolis.

<sup>a</sup>The values are shown as the mean ± SEM.<sup>b</sup><sup>\*\*</sup>P < 0.01 and <sup>\*\*\*</sup>P < 0.001 vs. control.

#### 4.4. Acetic Acid-Induced Writhing

As shown in Table 3, a significant decrease was observed in the number of writhes in the indomethacin ( $P < 0.001$ ) and EEP at 100 ( $P < 0.05$ ), 200 ( $P < 0.001$ ), and 400 ( $P < 0.001$ ) mg/kg. The inhibition percentage of the number of writhes with indomethacin and EEP at 100, 200, and 400 mg/kg are 78.96%, 21.73%, 38.96%, and 40.68%, respectively.

**Table 3.** Preventive Effect of EEP on Acetic Acid-Induced Writhing in Mice<sup>a,b</sup>

Treatments	N	Number of Writhes	Inhibition, %
Control	6	48.33 ± 1.14	-
Indomethacin	6	10.17 ± 1.30 <sup>***</sup>	78.96
EEP100	6	37.83 ± 2.77 <sup>*</sup>	21.73
EEP200	6	29.50 ± 2.32 <sup>***</sup>	38.96
EEP400	6	28.67 ± 2.60 <sup>***</sup>	40.68

Abbreviation: EEP, ethanolic extract of propolis.

<sup>a</sup>The values are shown as the mean ± SEM.<sup>b</sup><sup>\*\*</sup>P < 0.01 and <sup>\*\*\*</sup>P < 0.001 vs. control.

## 5. Discussion

In the present investigation, the administration of EEP showed potent anti-inflammatory effects in 2 models of inflammation, including xylene-induced ear edema and cotton pellet granuloma tests. In addition, administration of EEP showed potent antinociceptive effects in 2 models of pain, including formalin test and acetic acid-induced writhing test.

This is the first study conducted on anti-inflammatory and antinociceptive properties of Iranian propolis extracts. The present finding is supported by a previous study about antinociceptive and anti-inflammatory properties of hydroalcoholic extract of Brazilian red propolis (24). Xylene-induced ear edema is a simple and reliable model of acute inflammation for evaluating potential anti-inflammatory agents (38). This model of inflammation presumably is initiated by the release of histamine, kinin, fibrinolysin, and phospholipase A<sub>2</sub>. These

inflammatory intermediaries induce edema by vasodilation and increased vascular permeability (38-40). In this model, EEP was able to reduce acute inflammation in a dose-dependent manner. These results suggest that EEP may interfere with the actions of inflammatory mediators and produce anti-inflammatory effects. The cotton pellet granuloma is a convenient model for evaluating chronic inflammation. This type of inflammation is characterized by the proliferation of macrophages and fibroblasts as well as granulocyte infiltration (33, 41). The inhibitory effects of EEP may be due to the decrease of mentioned agents. The decrease in granuloma weight indicates that the anti-inflammatory activity of EEP was not in a dose-dependent manner. The inhibition percentage of granuloma weight produced by 200 mg/kg dose of EEP was significantly higher than that produced by the other two doses (100 and 400 mg/kg).

In this study, the antinociceptive activity of EEP was assessed using the acetic acid-induced writhing test and formalin test in mice. The writhing method induced by acetic acid is commonly described as a peripheral type of antinociceptive assessment of medicines (38, 42). The peripheral pain is initiated by the release of intermediaries such as bradykinin, lipoxygenases, substance P, prostaglandins and cyclooxygenases, as well as some cytokines such as interleukin-1 (IL-1), interleukin-8 (IL-8) and tumor necrosis factor (TNF) (38, 43). Formalin test is a valid model in analgesic studies that consists of 2 stages. The first stage (0 - 5 minutes) is characterized by neurogenic pain caused by direct stimulation of nociceptors. Substance P and bradykinin are thought to participate in this phase. The second stage (20 - 30 minutes) is specified by inflammatory pain, an action in which some inflammatory intermediaries are imagined to be involved, including histamine, prostaglandins, serotonin, and bradykinin. In fact, centrally acting medicines prevent both stages equally, while peripherally acting medicines prevent the second stage (38, 40, 44). In this study, EEP relieved the pain in 2 stages in a dose-dependent manner. The results obtained

from the formalin test were in agreement with the results from the writhing test, indicating that the extract had central and peripheral antinociceptive activities. The results obtained from inflammation and pain animal methods confirm that EEP may have the ability to reduce the production of inflammatory and pain response mediators.

It is known that phytochemicals such as flavonoids, phenolics, terpenoids, etc. have antinociceptive, anti-inflammatory, and antioxidant activities (45-48). Over 500 compounds such as flavonoids, phenolics, phenylpropanoids, terpenoids, stilbenes, lignans, coumarins, and their prenylated derivatives have been identified in propolis from many countries up to 2012 (49). Flavonoids have been widely shown to prevent the production of prostaglandins, arachidonic acid, histamine, bradykinins, etc., which participate in the inflammation and pain (50, 51). The major constituents of propolis, flavonoids, generally participated in pharmacological processes of Propolis. From 2000 to 2012, 112 flavonoids were identified in propolis. According to the chemical structure, flavonoids in propolis are arranged into flavones, flavonols, flavanones, flavanonols, chalcones, dihydrochalcones, isoflavones, isodihydroflavones, flavans, isoflavones, and neoflavonoids. In addition, flavonoid glycosides were identified that were very rare in propolis. They are isorhamnetin-3-O-rutinoside and flavone C-glycoside (49). Some studies previously described anti-inflammatory and antinociceptive activities of flavonoids. For instance, Chalcones have been introduced as selective cyclooxygenase-2 inhibitors (52). Also, isoflavone isolated from *Polygala molluginifolia* had an antinociceptive effect on mice (53).

Propolis is rich in phenolics, including cinnamic acid, p-coumaric acid, caffeic acid, ferulic acid, and their derivatives (52) that all of them were reported to possess anti-inflammatory and antinociceptive activities (54-57). Terpenoids isolated from propolis consist of types of monoterpenes and sesquiterpenes (49) that previous studies have shown the antinociceptive and anti-inflammatory activities of such compounds (58). Altogether, it can be concluded that ethanolic extract of propolis has potential anti-inflammatory activity against both acute (xylene-induced ear edema) and chronic inflammation (cotton pellet induced granuloma). The extract also shows antinociceptive activity, mediated both centrally (formalin test) and peripherally (acid-induced writhing test and formalin test). Therefore, it can be concluded that some chemical compounds in propolis may be responsible for the antinociceptive and anti-inflammatory activities.

## Footnotes

**Authors' Contribution:** Rahmatollah Parandin developed the original idea and the protocol, abstracted, analyzed data, and wrote the manuscript. Shahzad Daroogari contributed to the development of the protocol, abstracted data, and prepared the manuscript. The authors approved the final manuscript.

**Conflict of Interests:** The authors declare they have no conflict of interest.

**Ethical Approval:** This study was approved by the Research Ethics Committee of Payame Noor University (code: IR.PNU.REC.1397.080) and carried out according to the ethical guidelines for experimental investigation in animals.

**Funding/Support:** This study was conducted with the financial support of the University of Payame Noor University research grant (D/7/47416).

## References

1. Azab A, Nassar A, Azab AN. Anti-inflammatory activity of natural products. *Molecules*. 2016;**21**(10). doi: [10.3390/molecules21101321](https://doi.org/10.3390/molecules21101321). [PubMed: [27706084](https://pubmed.ncbi.nlm.nih.gov/27706084/)]. [PubMed Central: [PMC6274146](https://pubmed.ncbi.nlm.nih.gov/PMC6274146/)].
2. Medzhitov R. Origin and physiological roles of inflammation. *Nature*. 2008;**454**(7203):428-35. doi: [10.1038/nature07201](https://doi.org/10.1038/nature07201). [PubMed: [18650913](https://pubmed.ncbi.nlm.nih.gov/18650913/)].
3. Nathan C. Points of control in inflammation. *Nature*. 2002;**420**(6917):846-52. doi: [10.1038/nature01320](https://doi.org/10.1038/nature01320). [PubMed: [12490957](https://pubmed.ncbi.nlm.nih.gov/12490957/)].
4. Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. *Nat Immunol*. 2005;**6**(12):1191-7. doi: [10.1038/nri1276](https://doi.org/10.1038/nri1276). [PubMed: [16369558](https://pubmed.ncbi.nlm.nih.gov/16369558/)].
5. Simon SI, Green CE. Molecular mechanics and dynamics of leukocyte recruitment during inflammation. *Annu Rev Biomed Eng*. 2005;**7**:151-85. doi: [10.1146/annurev.bioeng.7.060804.100423](https://doi.org/10.1146/annurev.bioeng.7.060804.100423). [PubMed: [16004569](https://pubmed.ncbi.nlm.nih.gov/16004569/)].
6. Wang QS, Yang L, Cui WY, Chen L, Jiang YH. Anti-inflammatory and anti-nociceptive activities of methanol extract from aerial part of *Phlomis younghusbandii* Mukerjee. *PLoS One*. 2014;**9**(3): e89149. doi: [10.1371/journal.pone.0089149](https://doi.org/10.1371/journal.pone.0089149). [PubMed: [24598860](https://pubmed.ncbi.nlm.nih.gov/24598860/)]. [PubMed Central: [PMC3943724](https://pubmed.ncbi.nlm.nih.gov/PMC3943724/)].
7. Richard F, Michelle AC, Luigi XC. Opioids. In: Richard AH, Pamela CC, editors. *Lippincott's illustrated reviews*. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. 159 p.
8. Jagerovic N, Cano C, Elguero J, Goya P, Callado LF, Meana JJ, et al. Long-acting fentanyl analogues: Synthesis and pharmacology of N-(1-phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. *Bioorg Med Chem*. 2002;**10**(3):817-27. doi: [10.1016/S0968-0896\(01\)00345-5](https://doi.org/10.1016/S0968-0896(01)00345-5). [PubMed: [11814871](https://pubmed.ncbi.nlm.nih.gov/11814871/)].
9. Tielemans MM, van Rossum LG, Eikendal T, Focks JJ, Laheij RJ, Jansen JB, et al. Gastrointestinal symptoms in NSAID users in an 'average risk population': Results of a large population-based study in randomly selected Dutch inhabitants. *Int J Clin Pract*. 2014;**68**(4):512-9. doi: [10.1111/ijcp.12346](https://doi.org/10.1111/ijcp.12346). [PubMed: [24499203](https://pubmed.ncbi.nlm.nih.gov/24499203/)].
10. Roth SH. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy. *Drugs*. 2012;**72**(7):873-9. doi: [10.2165/11633740-000000000-00000](https://doi.org/10.2165/11633740-000000000-00000). [PubMed: [22564130](https://pubmed.ncbi.nlm.nih.gov/22564130/)].



11. Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. *Clin Med Res*. 2007;5(1):19–34. doi: [10.3121/cmr.2007.698](#). [PubMed: [17456832](#)]. [PubMed Central: [PMC1855338](#)].
12. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. *Arch Intern Med*. 2010;170(22):1968–76. doi: [10.1001/archinternmed.2010.391](#). [PubMed: [21149752](#)].
13. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. *Am Fam Physician*. 2006;74(8):1347–54. [PubMed: [17087429](#)].
14. Schiltenswolf M, Akbar M, Hug A, Pfuller U, Gantz S, Neubauer E, et al. Evidence of specific cognitive deficits in patients with chronic low back pain under long-term substitution treatment of opioids. *Pain Physician*. 2014;17(1):9–20. [PubMed: [24452649](#)].
15. Jungquist CR, Flannery M, Perlis ML, Grace JT. Relationship of chronic pain and opioid use with respiratory disturbance during sleep. *Pain Manag Nurs*. 2012;13(2):70–9. doi: [10.1016/j.pmn.2010.04.003](#). [PubMed: [22652280](#)].
16. Reddy RG, Aung T, Karaviti N, Wass JA. Opioid induced hypogonadism. *BMJ*. 2010;341:c4462. doi: [10.1136/bmj.c4462](#). [PubMed: [20807731](#)]. [PubMed Central: [PMC2974597](#)].
17. Rothwell PE, Thomas MJ, Gewirtz JC. Protracted manifestations of acute dependence after a single morphine exposure. *Psychopharmacology (Berl)*. 2012;219(4):991–8. doi: [10.1007/s00213-011-2425-y](#). [PubMed: [21833504](#)]. [PubMed Central: [PMC3978778](#)].
18. Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, Keshavarzian A. Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders. *Complement Ther Med*. 2007;15(3):207–16. doi: [10.1016/j.ctim.2006.06.005](#). [PubMed: [17709066](#)].
19. Ahmed S, Anuntyio J, Malemud CJ, Haqqi TM. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: A review. *Evid Based Complement Alternat Med*. 2005;2(3):301–8. doi: [10.1093/ecam/neh117](#). [PubMed: [16136208](#)]. [PubMed Central: [PMC1193557](#)].
20. Marcucci MC, Ferreres F, Garcia-Viguera C, Bankova VS, De Castro SL, Dantas AP, et al. Phenolic compounds from Brazilian propolis with pharmacological activities. *J Ethnopharmacol*. 2001;74(2):105–12. doi: [10.1016/S0378-8741\(00\)00326-3](#). [PubMed: [11167028](#)].
21. Almeida E, Menezes H. Anti-inflammatory activity of propolis extracts: A review. *J Venom Anim Toxins*. 2002;8(2):191–212. doi: [10.1590/S0104-79302002000200002](#).
22. Banskota AH, Tezuka Y, Prasain JK, Matsushige K, Saiki I, Kadota S. Chemical constituents of Brazilian propolis and their cytotoxic activities. *J Nat Prod*. 1998;61(7):896–900. doi: [10.1021/np980028c](#). [PubMed: [9677271](#)].
23. Alencar SM, Oldoni TL, Castro ML, Cabral IS, Costa-Neto CM, Cury JA, et al. Chemical composition and biological activity of a new type of Brazilian propolis: Red propolis. *J Ethnopharmacol*. 2007;113(2):278–83. doi: [10.1016/j.jep.2007.06.005](#). [PubMed: [17656055](#)].
24. Lima Cavendish R, de Souza Santos J, Belo Neto R, Oliveira Paixao A, Valeria Oliveira J, Divino de Araujo E, et al. Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents. *J Ethnopharmacol*. 2015;173:127–33. doi: [10.1016/j.jep.2015.07.022](#). [PubMed: [26192808](#)].
25. Gomez-Caravaca AM, Gomez-Romero M, Arraez-Roman D, Segura-Carretero A, Fernandez-Gutierrez A. Advances in the analysis of phenolic compounds in products derived from bees. *J Pharm Biomed Anal*. 2006;41(4):1220–34. doi: [10.1016/j.jpba.2006.03.002](#). [PubMed: [16621403](#)].
26. Silva-Carvalho R, Baltazar F, Almeida-Aguiar C. Propolis: A complex natural product with a plethora of biological activities that can be explored for drug development. *Evid Based Complement Alternat Med*. 2015;2015:206439. doi: [10.1155/2015/206439](#). [PubMed: [26106433](#)]. [PubMed Central: [PMC4461776](#)].
27. Borrelli F, Maffia P, Pinto L, Ianaro A, Russo A, Capasso F, et al. Phytochemical compounds involved in the anti-inflammatory effect of propolis extract. *Fitoterapia*. 2002;73 Suppl 1:S53–63. doi: [10.1016/S0367-326X\(02\)00191-0](#). [PubMed: [12495710](#)].
28. Wang D, Xiang DB, He YJ, Li ZP, Wu XH, Mou JH, et al. Effect of caffeic acid phenethyl ester on proliferation and apoptosis of colorectal cancer cells in vitro. *World J Gastroenterol*. 2005;11(26):4008–12. doi: [10.3748/wjg.v11.i26.4008](#). [PubMed: [15996024](#)]. [PubMed Central: [PMC4502095](#)].
29. Ramos AFN, Miranda JL. Propolis: A review of its anti-inflammatory and healing actions. *J Venom Anim Toxins Incl Trop Dis*. 2007;13(4):697–710. doi: [10.1590/S1678-91992007000400002](#).
30. Park YK, Ikegaki M. Preparation of water and ethanolic extracts of propolis and evaluation of the preparations. *Biosci Biotechnol Biochem*. 1998;62(11):2230–2. doi: [10.1271/bbb.62.2230](#). [PubMed: [27393593](#)].
31. Ramezani M, Nasri S, Yassa N. Antinociceptive and anti-inflammatory effects of isolated fractions from Apium graveolens seeds in mice. *Pharm Biol*. 2009;47(8):740–3. doi: [10.1080/13880200902939283](#).
32. González Mosquera DM, Ortega YH, Kilonda A, Dehaen W, Pieters L, Apers S. Evaluation of the in vivo anti-inflammatory activity of a flavonoid glycoside from *Boldoa purpurascens*. *Phytochem Lett*. 2011;4(3):231–4. doi: [10.1016/j.phytol.2011.04.004](#).
33. Su JY, Li QC, Zhu L. Evaluation of the in vivo anti-inflammatory activity of a flavone glycoside from *Candelia discoidea* (Ledeb.) Poljak. *EXCLI J*. 2011;10:110–6. [PubMed: [27857669](#)]. [PubMed Central: [PMC5109022](#)].
34. Hajhashemi V, Ghannadi A, Hajiloo M. Analgesic and anti-inflammatory effects of rosa damascena hydroalcoholic extract and its essential oil in animal models. *Iran J Pharm Res*. 2010;9(2):163–8. [PubMed: [24363723](#)]. [PubMed Central: [PMC3862064](#)].
35. de Miranda FG, Vilar JC, Alves IA, Cavalcanti SC, Antonioli AR. Antinociceptive and antiedematogenic properties and acute toxicity of *Tabebuia avellanae* Lor. ex Griseb. inner bark aqueous extract. *BMC Pharmacol*. 2001;1:6. doi: [10.1186/1471-2210-1-6](#). [PubMed: [11574048](#)]. [PubMed Central: [PMC56902](#)].
36. Gawade SP. Acetic acid induced painful endogenous infliction in writhing test on mice. *J Pharmacol Pharmacother*. 2012;3(4):348. doi: [10.4103/0976-500X.103699](#). [PubMed: [23326113](#)]. [PubMed Central: [PMC3543562](#)].
37. Yin ZY, Li L, Chu SS, Sun Q, Ma ZL, Gu XP. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. *Sci Rep*. 2016;6:27129. doi: [10.1038/srep27129](#). [PubMed: [27272194](#)]. [PubMed Central: [PMC4895225](#)].
38. Zhang Y, Shu Z, Yin L, Ma L, Wang X, Fu X. Anti-inflammatory and antinociceptive activities of non-alkaloids fractions from *Aconitum flavum* in vivo. *Rev Bras Farmacogn*. 2015;25(1):47–52. doi: [10.1016/j.bjp.2014.11.013](#).
39. Li YC, Xian YF, Ip SP, Su ZR, Su JY, He JJ, et al. Anti-inflammatory activity of patchouli alcohol isolated from *Pogostemonis Herba* in animal models. *Fitoterapia*. 2011;82(8):1295–301. doi: [10.1016/j.fitote.2011.09.003](#). [PubMed: [21958968](#)].
40. Xu Q, Wang Y, Guo S, Shen Z, Wang Y, Yang L. Anti-inflammatory and analgesic activity of aqueous extract of *Flos populi*. *J Ethnopharmacol*. 2014;152(3):540–5. doi: [10.1016/j.jep.2014.01.037](#). [PubMed: [24508857](#)].
41. Ma J, Guo C, Pan Y, Lin D, Qiu L, Wen L. Antioxidant and anti-inflammatory activities of ethyl acetate extract of *Gynura formosana* (Kitam) leaves. *Exp Ther Med*. 2017;14(3):2303–9. doi: [10.3892/etm.2017.4757](#). [PubMed: [28962159](#)]. [PubMed Central: [PMC5609154](#)].
42. Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D. Preclinical assessment of candidate analgesic drugs: Recent advances and future challenges. *J Pharmacol Exp Ther*. 2006;319(2):507–14. doi: [10.1124/jpet.106.106377](#). [PubMed: [16751251](#)].
43. Sarmento-Neto JF, do Nascimento LG, Felipe CF, de Sousa DP. Analgesic potential of essential oils. *Molecules*. 2015;21(1):E20. doi:

- [10.3390/molecules21010020](#). [PubMed: [26703556](#)]. [PubMed Central: [PMC6273222](#)].
44. Zakaria ZA, Ghani ZD, Nor RN, Gopalan HK, Sulaiman MR, Jais AM, et al. Antinociceptive, anti-inflammatory, and antipyretic properties of an aqueous extract of *Dicranopteris linearis* leaves in experimental animal models. *J Nat Med*. 2008;**62**(2):179–87. doi: [10.1007/s11418-007-0224-x](#). [PubMed: [18404320](#)].
  45. Murugan R, Parimelazhagan T. Study of anti-nociceptive, anti-inflammatory properties and phytochemical profiles of *Osbeckia parvifolia* Arn. (Melastomataceae). *Ind Crops Prod*. 2013;**51**:360–9. doi: [10.1016/j.indcrop.2013.09.035](#).
  46. Wang Y, Chen P, Tang C, Wang Y, Li Y, Zhang H. Antinociceptive and anti-inflammatory activities of extract and two isolated flavonoids of *Carthamus tinctorius* L. *J Ethnopharmacol*. 2014;**151**(2):944–50. doi: [10.1016/j.jep.2013.12.003](#). [PubMed: [24333963](#)].
  47. Yamanishi R, Yoshigai E, Okuyama T, Mori M, Murase H, Machida T, et al. The anti-inflammatory effects of flavanol-rich lychee fruit extract in rat hepatocytes. *PLoS One*. 2014;**9**(4). e93818. doi: [10.1371/journal.pone.0093818](#). [PubMed: [24705335](#)]. [PubMed Central: [PMC3976307](#)].
  48. Fazio A, Plastina P, Meijerink J, Witkamp RF, Gabriele B. Comparative analyses of seeds of wild fruits of *Rubus* and *Sambucus* species from Southern Italy: Fatty acid composition of the oil, total phenolic content, antioxidant and anti-inflammatory properties of the methanolic extracts. *Food Chem*. 2013;**140**(4):817–24. doi: [10.1016/j.foodchem.2012.11.010](#). [PubMed: [23692771](#)].
  49. Huang S, Zhang CP, Wang K, Li GQ, Hu FL. Recent advances in the chemical composition of propolis. *Molecules*. 2014;**19**(12):19610–32. doi: [10.3390/molecules191219610](#). [PubMed: [25432012](#)]. [PubMed Central: [PMC6271758](#)].
  50. Amresh G, Reddy GD, Rao Ch V, Singh PN. Evaluation of anti-inflammatory activity of *Cissampelos pareira* root in rats. *J Ethnopharmacol*. 2007;**110**(3):526–31. doi: [10.1016/j.jep.2006.10.009](#). [PubMed: [17097249](#)].
  51. Mirazi N, Hosseini A. Evaluation of antinociceptive activity of berberis vulgaris L. Fruit's hydroethanolic extract in male mice. *Iran J Pharm Sci*. 2013;**9**(14):15–22.
  52. Razmi A, Zarghi A, Arfaee S, Naderi N, Faizi M. Evaluation of anti-nociceptive and anti-inflammatory activities of novel chalcone derivatives. *Iran J Pharm Res*. 2013;**12**(Suppl):153–9. [PubMed: [24250683](#)]. [PubMed Central: [PMC3813361](#)].
  53. Nucci-Martins C, Nascimento LF, Venzke D, Brethanha LC, Sako AV, Oliveira AS, et al. Antinociceptive effect of hydroalcoholic extract and isoflavone isolated from *Polygala molluginifolia* in mice: Evidence for the involvement of opioid receptors and TRPV1 and TRPA1 channels. *Phytomedicine*. 2016;**23**(5):429–40. doi: [10.1016/j.phymed.2016.02.002](#). [PubMed: [27064002](#)].
  54. Fernandez MA, Saenz MT, Garcia MD. Anti-inflammatory activity in rats and mice of phenolic acids isolated from *Scrophularia frutescens*. *J Pharm Pharmacol*. 1998;**50**(10):1183–6. doi: [10.1111/j.2042-7158.1998.tb03332.x](#). [PubMed: [9821668](#)].
  55. Yonathan M, Asres K, Assefa A, Bucar F. In vivo anti-inflammatory and anti-nociceptive activities of *Cheilanthes farinosa*. *J Ethnopharmacol*. 2006;**108**(3):462–70. doi: [10.1016/j.jep.2006.06.006](#). [PubMed: [16876348](#)].
  56. Xu Y, Lin D, Yu X, Xie X, Wang L, Lian L, et al. The antinociceptive effects of ferulic acid on neuropathic pain: Involvement of descending monoaminergic system and opioid receptors. *Oncotarget*. 2016;**7**(15):20455–68. doi: [10.18632/oncotarget.7973](#). [PubMed: [26967251](#)]. [PubMed Central: [PMC4991467](#)].
  57. Zhao Y, Liu J. Anti-Inflammatory Effects of p-coumaric Acid in LPS-Stimulated RAW264.7 Cells: Involvement of NF- $\kappa$ B and MAPKs Pathways. *Med Chem*. 2016;**6**(5):327–30. doi: [10.4172/2161-0444.1000365](#).
  58. de Cassia da Silveira ER, Lima TC, da Nobrega FR, de Brito AEM, de Sousa DP. Analgesic-like activity of essential oil constituents: An update. *Int J Mol Sci*. 2017;**18**(12). doi: [10.3390/ijms18122392](#). [PubMed: [29232831](#)]. [PubMed Central: [PMC5751100](#)].